

---

## **Virtual Screening of Solanine and its derivatives to analyze inhibitory activity towards Acetylcholinesterase for the treatment of Alzheimer's disease**

**JITENDRA GUPTA**

Compcc.org

A Virtual informatics research organization  
Department of Bioinformatics  
St. Aloysius College (Autonomous),  
Post – Kotekar, Madoor, Beeri,  
Mangalore, Karnataka  
India

**PRASHANT SAXENA**

Compcc.org

A Virtual informatics research organization  
Department of Bioinformatics  
Sathyabama University  
Chennai, Tamilnadu  
India

**ROHIT THAKUR<sup>1</sup>**

Compcc.org

A Virtual informatics research organization  
Department of Bioinformatics  
VIT University,  
Katpadi, Vellore, Tamil Nadu  
India

**INAMUL HASAN MADAR**

Compcc.org

A Virtual informatics research organization  
Department of Biotechnology and Bioinformatics  
Bishop Heber College (Autonomous),  
Tiruchirappalli, Tamil Nadu  
India

---

<sup>1</sup> Corresponding Author: rohit@compcc.org

**Abstract:**

*Alzheimer's disease (AD) is most common form of dementia affecting elderly people, and sixth leading cause of death worldwide. The two abnormal structures formed in AD patient's brain are beta-amyloid plaques and neurofibrillary. The beta-amyloid plaque formation is accelerated due to acetylcholinesterases. Treatment of AD has majorly dependent on inhibition of acetylcholinesterase. In the present study, acetylcholinesterase receptor is docked with solanine and its derivatives and with a commercially available drug. The lead 3 compounds, are selected based on minimum binding energy and interaction with the active site of the receptor, are much better compared to commercially available drug. Molecular interactions of the receptor complexes with lead solanine compounds are also found to be higher in number. By this it can be hypothesize that solanine derivatives can inhibit acetylcholinesterase more effectively, which controls rapid breaking of acetylcholine, a neurotransmitter to acetyl and choline and aid in Alzheimer's treatment.*

**Key words:** Alzheimer's disease, Acetylcholinesterase receptor, Solanine, Donepezil, Neurotransmitter, Dementia, Docking

**Introduction**

Alzheimer's disease (AD) is most common form of dementia affecting elderly people, and sixth leading cause of death worldwide. AD is characterized by weak memory, changes in behaviour, inability to recognize languages and loss of IQ, is a very complex and progressive neurodegenerative disease (Ferri CP et al., 2005, Birks J, 2006, ADEAR, 2013). Many pathological conditions indicate symptoms of AD, such as improper functioning of cholinergic system, halted functioning of homeostasis of biometals and increased accumulation of beta-amyloids (Zhou, X. et al., 2010, Tang, H. et al., 2007). The two abnormal structures formed in AD patient's brain are beta-amyloid plaques and neurofibrillary (Mattson, 2004). These

beta-amyloid plaque formation is accelerated due to acetylcholinesterase enzyme; biochemical studies explain (Inestrosa, 2008). Thus development of effective treatment for AD has majorly dependent on inhibition of acetylcholinesterase (Peter J H et al., 2006, Maheshwari U, 2010).

Acetylcholinesterase enzyme hydrolyses the neurotransmitter acetylcholine very rapidly and completely stops neurotransmission at synaptic cleft (Hay D et al., 2010). Acetylcholinesterase inhibitors are the standard of therapy and are the only class of drugs approved by the Food and Drug Administration (FDA) to treat AD patients (Cummings JL, 2003). Donepezil is the first market available drug to treat AD, is not much effective in modulating disease process and shows most common side effects like dizziness, cramps, fatigue, diarrhoea despite of its specificity to acetylcholinesterase (Mark H et al., 2002), which encourages to discover new acetylcholinesterase inhibitors.

Solanine, belongs to solanaceae family is a glycoalkaloid and poisonous in nature. It is present in all parts of the plant. Solanine shows pesticidal and fungicidal effects as a defend mechanism. First time it was extracted by Desfosses from the berries of the European black nightshade *Solanum nigrum* in 1820 (Desfosses, 1820). Solanine has an inhibitory activity towards cholinesterases (Harries et al., 1962; McGhee et al., 2000). It helps in acetylcholine breakage into acetyl and choline by inhibiting the fast production of acetylcholinesterases, which maintains the level of acetylcholine, a neurotransmitter and ultimately treats AD.


Docking of macromolecule with ligands aids in predicting the intermolecular interaction of the complex formed, which plays very important role in development of new drugs. Molecular interaction studies help in understanding the modification in functioning of macromolecule upon interaction with ligand. Autodock4 provides very good results of docking of

ligand in cavity of the macromolecule when compared with experimental data. The aim of the study is to retrieve the potential free energy and molecular interactions from complex formed between receptor human acetylcholinesterase and solanine and its analogous obtained by Autodock4, Compare these results with complex of receptor human acetylcholinesterase with donepezil, a market available acetylcholinesterase inhibitor.

## **Methodology**

The protein Data Bank (PDB), a single worldwide archive of structural data of biomolecules, was established in 1971 at Brookhaven National Laboratories (Berman et al., 2000). It contains X-ray crystallography and NMR method determined structural records of the macromolecules. The database is maintained by Research collaboratory for structural bioinformatics (RCSB), as on Apr 08, 2014 PDB has 99293 macromolecular structures data entries.

The Crystal structure of receptor human acetylcholinesterase, PDB ID 3LII, molecular weight 120180.53 is obtained from PDB database, see figure1. The structure is determined using X-ray diffraction method, having 3.20 Armstrong resolutions. It consists of two amino acids chains A and B, have unique sequences. Length of each chain is 540 amino acids. There are 24 helices and 25 strands in the structure. The additional ligands which are present along with the structure are removed using Chimera, a visualization system for exploratory research and analysis (Pettersen et al., 2004). The structure is energy optimized using Discovery Studio 2.0, a molecular modelling environment (need citation)



**Figure1**-Acetylcholinesterase Chain-A

The PubChem Compound, a database for validated chemical structures information. The structures stored in this are pre-clustered and cross-referenced based on their identity and similarity. The structure of donepezil Pubchem ID CID 3152 and solanine with PubChem ID CID 262500 and 76 other compounds similar to it, are retrieved from PubChem Compound Database. Molecular weight of these compounds ranges from 379.49 [g/mol] to 1192.34 [g/mol].

The minimum energy with most stable conformations of these compounds are computed using Avogadro, a software for advanced semantic chemical editing, visualization, and analysis (Marcus D Hanwell et al., 2012), which are used in docking with macromolecule.

Autodock is most widely used open source docking software in structure based analysis and prediction of biomolecular complexes. It has a set of protocols to pre-process the macromolecules and the small compound to make them suitable for docking, which involves deciding the atom type, hydrogen addition/removal, file format conversion, grid parameter and dock parameter setting. Autodock implies Lamarckian Genetic Algorithm along with empirical free energy force field to predict the highly stable bonded conformations with maximum free energies of associations (Morris, G. M., et al., 2009).


In this study protein-ligand rigid docking, a unique method of docking of ligand to the known active site of protein is used. The macromolecule with PDB ID 3LII and solanine and its analogues are loaded to the software one at a time and the series of protocols are applied to obtain the most stable binding poses.

Computation of number of hydrogen bond interactions using Chimera and poses with minimum binding energies for each complex, are saved in a tabular form (table 1). To visualize the interactions in the complex Ligplot, a software program to generate schematic diagrams of protein-ligand interactions is used (Wallace A C et al., 1995).


## **Results and Discussions**

The receptor human acetylcholinesterase has chain A and chain B, are sequence unique with same binding pocket, due to which only one chain (chain A) is used for docking (see figure 1). Molecular docking of receptor with the ligands has been very challenging task to predict the binding energies.


The docking results of 78 receptor-ligand complexes shows that the binding energies are in the range of -11.89kcal/mol to +1556.25kcal/mol, with minimum binding energy being -11.89 kcal/mol. The lead 3 compounds, PubChem ID CID 25245074, CID 25245075, CID 5351499 with binding energies -10.77kcal/mol, -10.11kcal/mol, -9.22kcal/mol respectively are selected based on minimum binding energy and at the active site residue Phe295 of the receptor, are much better compared to market available drug donepezil (PubChem ID CID 3152) with binding energy -6.94kcal/mol, see figure 2,3,4,5. Number of hydrophobic interaction in receptor complexed with these lead compounds are higher than donepezil, which are listed in table 1. These interactions can be seen in figure 6,7,8,9. The interacting residues in these complexes are listed in table 2.




**Figure2** – Chemical structure of Gamma – solanine (Pubchem ID - CID 25245074)




**Figure3** - Chemical structure of CID 25245074




**Figure4** - Chemical structure of Isorubijervosine (Pubchem ID - CID 25245075)




**Figure5** - Chemical structure of Donepezil (Pubchem ID - CID 3152)




**Figure6** - Interaction of Acetylcholinesterase – Solanine analogue (PubChem ID - CID 25245074)



**Figure7** - Interaction of Acetylcholinesterase – Solanine analogue (PubChem ID – CID 25245075)



**Figure 8** - Interaction of Acetylcholinesterase – Solanine analogue (PubChem ID - CID 5351499)



**Figure 9** - Interaction of Acetylcholinesterase – Solanine analogue (PubChem ID - CID 5351499)

**Table 1** - List of top 3 solanine analogues and donepezil with binding energy and no. of hydrogen bonds

Compound Name	PubChem ID	Binding Energy	No. of hydrogen bonds
Gamma solanine	CID 25245074	-10.77	11
-----	CID 25245075	-10.11	9
Isorubijervosine	CID 5351499	-9.22	11
Donepezil	CID 3152	-6.71	7

**Table 2** – List of interacting residues in Acetylcholinesterase complexed with top 3 solanine analogues and donepezil

Receptor	Compound Name	PubChem ID	Interacting Residues
Acetylcholinesterase (PDB ID - 3LII)	Gamma solanine	CID 25245074	Tyr124, Trp286, His287, Leu289, Gln291, Glu292, Val294, Phe295, Tyr341
	-----	CID 25245075	Tyr72, Tyr124, Trp286, His287, Leu289, Gln291, Glu292, Ser293, Val294, Phe295, Phe338,

			Tyr341
	Isorubijervosine	CID 5351499	Tyr124, Trp286, His287, Leu289, Pro290, Gln291 Ser293, Val294, Phe295 Phe338, Tyr341
	Donepezil	CID 3152	Tyr72, Trp86, Tyr124, Glu202, Ser203, Trp286 Ser293, Phe295, Tyr337 Phe338, Tyr341, His447 Gly448

## Conclusions

Protein-ligand interaction is crucial part of drug designing. In the study, receptor human acetylcholinesterase is docked with ligand solanine and its analogues in search to find anti-acetylcholinesterase molecule cheaper, largely accessible from nature with lesser side effects in contrast to chemically synthesized drugs like donepezil for treating Alzheimer's disease. Autodock4 tool is used to retrieve the most precise binding poses and higher number of molecular binding interactions between receptor human acetylcholinesterase and solanine and its analogous. The interactions visualized using LigPlot software shown to be very much stable, which lets to hypothesize that solanine analogues can inhibit acetylcholinesterase more effectively, which will control rapid breaking of acetylcholine, a neurotransmitter to acetyl and choline and treat AD patients.

## REFERENCES

- ADEAR (Alzheimer's disease Education and Referral Center). 2013.<http://www.nia.nih.gov/alzheimers/topics/alzheimers-basics>
- Berman, H.M., John, W., Zukang, F., Gary, G., Bhat, T.N., Helge, W., Ilya, N.S., and Philip, E.B. 2000. "The Protein Data Bank." *Nucleic Acids Research* 28(1):235-242. doi:10.1093/nar/28.1.235
- Birks, J. Cochrane. 2006. "Cholinesterase inhibitors for Alzheimer's disease." *Database of Systematic Reviews* 1: Art. No.: CD005593. doi: 10.1002/14651858.CD005593.
- Bolton, E., Wang, Y., Thiessen, P.A. and Bryant, S.H. 2008. "PubChem - Integrated Platform of Small Molecules and Biological Activities." Chapter 12 IN *Annual Reports in Computational Chemistry*, Volume 4, American Chemical Society, Washington, DC.
- Cummings, J.L. 2003. "Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations." *Psychiatry* 11(2):131-45.
- Ferri, CP, Prince, M, Brayne, C., Brodaty, H, Fratiglioni, L, Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y, Jorm, A., Mathers, C., Menezes, P.R., Rimmer, E., and Sczufca, M. 2005. "Global prevalence of dementia - A delphi consensus study." *Alzheimer's Disease International Lancet*. 366(9503):2112-7. doi:10.1016/S0140-6736(05)67889-0
- Hanwell, Marcus D., Donald E. Curtis, David C. Lonie, Tim Vandermeersch, Eva Zurek and Geoffrey R. Hutchison. 2012. "Avogadro: An advanced semantic chemical editor, visualization, and analysis platform." *Journal of Cheminformatics* 13 Aug. doi:10.1186/1758-2946-4-17
- Hay, D., Israel, S., Michal, H., Terrone, L.R., and Joel, L.S. 2010. "Acetylcholinesterase: From 3D Structure to Function." *Chemico-Biological Interactions* 187(1-3): 10-

22.doi:10.1016/j.cbi.2010.01.042

- Inestrosa, N.C., Dinamarca, M.C. and Alvarez, A. 2008. "Amyloid-cholinesterase interactions, Implications for Alzheimer's disease." *Federation of biomedical societies Journal* 275:625-32. doi:10.1111/j.1742-4658.2007.06238.x
- Mattson, M.P. "Pathways towards and away from Alzheimer's disease." *Nature* (2004): 430:631-9, 2004.doi:10.1038/nature02621.
- Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S. and Olson, A. J. 2009. "Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility." *Journal of Computational Chemistry* 16: 2785-91. doi:10.1002/jcc.21256
- Peter, J. Houghton, Yuhao Ren and Melanie-Jayne Howes. 2006. "Acetylcholinesterase inhibitors from plants and fungi." *Natural Product Reports* 23: 181-199.doi:10.1039/B508966M
- Petterson, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C. and Ferrin, T.E. 2004. "Chimera - A visualization system for exploratory research and analysis." *Journal of Computational Chemistry* 25(13): 1605-12. doi:10.1002/jcc.20084
- Tang, H., Zhao H.-T., Zhong, S.-M., Wang, Z.-Y., Chen, Z.-F. and Liang, H. 2010. "Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation." *Bioorganic and Medicinal Chemistry Letters* 22: 2257.doi:10.1016/j.bmcl.2012.01.090
- Wallace, A. C., Laskowski, R. A. and Thornton, J. M. 1995. "LIGPLOT - A program to generate schematic diagrams of protein-ligand interactions." *Protein Engineering Design and Selection* 8: 127-134. doi:10.1093/protein/8.2.127
- Zhou, X., Li, M., Wang, X.-B., Wang, T. and Kong, L.-Y. 2010.

“Synthesis of Benzofuran Derivatives via Rearrangement and Their Inhibitory Activity on Acetylcholinesterase.” *Molecules* 15: 8593-8601.  
doi:10.3390/molecules15128593

### **Note on Authors:**

**JITENDRA GUPTA** (Email ID – [jitendra@compcyc.org](mailto:jitendra@compcyc.org)) Jitendra is currently working as a Senior Research Scientist in CompCyc – A Virtual Informatics Research Organisation. He is also a core committee member of ISCB regional student group – India. Jitendra did his Masters in Bioinformatics from Mangalore University. A short period of time he worked in Manipal Institute of technology as a research scholar. For his strong interest in molecular modelling and simulation studies he joined Open source drug discovery project (an initiative by CSIR) in Indian Institute of Science. There his work was focused on adding extensions to open source cheminformatics software's. His area of interest includes Proteomics, Homology Modeling, Computational Biology, In-silico drug designing, Systems Biology and Genomics.

**PRASHANT SAXENA** (Email ID – [prashant@compcyc.org](mailto:prashant@compcyc.org)) Prashant is currently working as a Junior Research Scientist in CompCyc – A virtual informatics research organisation. He is also a core committee member of ISCB regional student group – India. Prashant holds a Bachelors of Technology and pursuing Masters of Technology in the field of Bioinformatics. He has a number of poster and paper presentations at various International conferences and seminars to his credit. Adept at the basic concepts of his subject, his special areas of interest are dynamic and of great importance keeping in mind the futuristic vision of the work he would like to be involved in. with a broad minded positive approach in the face of even the most difficult of circumstances, his enthusiasm and dedication towards the work at hand makes him an invaluable asset for his team. His area of interest includes Molecular Modeling and Simulation, DNA and Protein Sequence Analysis and Drug designing.

**ROHIT THAKUR** (Email ID – rohit@compcyc.org) Rohit is currently working as a Junior Research Scientist in CompCyc – A virtual informatics research organisation. He is also a core committee member of ISCB regional student group – India. Rohit is pursuing his Bachelor's of Technology degree from VIT University, Vellore. His area of interest includes Computational Biology, Data mining and Visualisation, Transcriptomics, Systems Biology, Genomics, Nano-Biosensors

**Publication:** “Low-cost and eco-friendly phyto- synthesis of silver nanoparticles using Cocos nucifera coir extract and its larvicidal activity” paper published in ELSEVIER Journal Industrial Crops and Products (Volume 43, May 2013, 631- 635).

**INAMUL HASAN MADAR** (Email ID – inam@compcyc.org) Inamul is director of CompCyc – A virtual informatics research organisation. He is secretary / Vice President of ISCB regional student group – India. He is also currently working as Assistant Professor in the Department of Biotechnology and Bioinformatics, Bishop Heber College, India. Inamul did his Masters in Bioinformatics from Bharathidasan University. A short period of time he worked in iPro Technologies Pvt Ltd, A Bioinformatics research center as a research Guide. For his strong interest in bioinformatics and proteomics studies, he joined with Prof. Hans Uwe Dahms, Sanmyung University, Seoul, South Korea. His area of interest includes Proteomics and Mass Spectrometry, Onco- Informatics, Computational Biology, In-Silico drug designing, Systems Biology, Genomics.